BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex ↗

June 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc...

Via Benzinga

BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Solid Tumors

June 07, 2021

From BeiGene, Ltd.

Via Business Wire

The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck ↗

June 07, 2021

Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,...

Via Benzinga

BeiGene Presents Clinical Data from Two Pivotal Trials of Tislelizumab at the 2021 ASCO Annual Meeting

June 04, 2021

From BeiGene, Ltd.

Via Business Wire

BeiGene Presents Clinical Data from Two Phase 2 Trials of Pamiparib at the 2021 ASCO Annual Meeting

June 04, 2021

From BeiGene, Ltd.

Via Business Wire

BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021

June 01, 2021

From BeiGene, Ltd.

Via Business Wire

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗

May 31, 2021

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...

Via Benzinga

Week In Review: LianBio Acquires Two IBD Candidates In $218 Million Deal ↗

May 22, 2021

LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200...

Via Talk Markets

BeiGene's Tislelizumab Shows Progression-Free Survival Benefit in Type Of Head & Neck Cancer ↗

May 21, 2021

BeiGene Ltd (NASDAQ: BGNE) has announced topline results from the Phase 3 RATIONALE 309 trial evaluating tislelizumab combined with chemotherapy as a...

Via Benzinga

BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

May 21, 2021

From BeiGene, Ltd.

Via Business Wire

BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting

May 19, 2021

From BeiGene, Ltd.

Via Business Wire

BeiGene's Brukinsa US Application For Expanded Use Under FDA Review ↗

May 19, 2021

The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application for Brukinsa (zanubrutinib) for marginal zone lymphoma (MZL)...

Via Benzinga

BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma

May 19, 2021

From BeiGene, Ltd.

Via Business Wire

BeiGene Highlights Progress in Hematology at EHA2021 Virtual Congress

May 12, 2021

From BeiGene, Ltd.

Via Business Wire

Week In Review: WHO Close To Approving Global Use For Two China COVID-19 Vaccines ↗

May 08, 2021

The World Health Organization approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the pandemic. Sinovac's inactivated COVID-19 vaccine...

Via Talk Markets

China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer

May 07, 2021

From BeiGene, Ltd.

Via Business Wire

BeiGene Reports First Quarter 2021 Financial Results

May 06, 2021

From BeiGene, Ltd.

Via Business Wire

This Is Why Humira Isn't AbbVie's Biggest Problem Right Now ↗

May 03, 2021

Two of AbbVie's most important assets could get a lot harder to sell.

Via The Motley Fool

Topics Intellectual Property

A Heavy News Day And Crypto ↗

April 28, 2021

Israeli TEVA reported Q1 sales which missed forecasts at $4 bn, leading to a 2.6% drop in its price earlier today.

Via Talk Markets

BeiGene's Stock Is Trading Higher As Brukinsa Drug On Par With JNJ's Imbruvica In Late-Stage Blood Cancer Studies ↗

April 28, 2021

BeiGene Ltd (NASDAQ: BGNE) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing Brukinsa (zanubrutinib) against...

Via Benzinga

BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia

April 28, 2021

From BeiGene

Via Business Wire

Exceptions To A Low Period ↗

April 25, 2021

This past week served as a negative period for my stock holdings, with a couple of exceptions. Here I discuss what those exceptions were and how they moved.

Via Talk Markets

Currency Manipulation ↗

April 16, 2021

London's FTSE 100 index today rose over 7000 for the first time in 14 months. It hit 7019.53.

Via Talk Markets

BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021

April 12, 2021

From BeiGene, Ltd.

Via Business Wire

BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021

April 11, 2021

From BeiGene, Ltd.

Via Business Wire

Week In Review: Sorrento Acquires ACEA In $488 Million Deal Between Two San Diego-China Oncology Biopharmas ↗

April 10, 2021

Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Both companies develop novel cancer drugs, both are headquartered in San Diego and both have operations in...

Via Talk Markets

The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight ↗

April 10, 2021

Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of...

Via Benzinga

Heavy News Day - Cheats ↗

April 08, 2021

US job losses were up 744,000 vs a forecast of 694,000.

Via Talk Markets

BeiGene's Zanubrutinib Fails To Meet Efficacy Endpoints In Mid-Stage COVID-19 Study ↗

April 08, 2021

BeiGene Ltd (NASDAQ: BGNE) has announced data from Phase 2 trial evaluating Brukinsa (zanubrutinib) in hospitalized COVID-19 patients, requiring...

Via Benzinga

BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress

April 08, 2021

From BeiGene, Ltd.

Via Business Wire

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.